BioMedical Enterprises, Inc. (BME) Announces the Appointment of Kenneth I. Moch as President and Chief Executive Officer
BME specializes in nitinol implants that contract and compress bone after implantation, bringing bone ends together to promote bone union. These proprietary implants allow the surgeon to finely control the amount of compression and rate of force application generated on bones, thereby reducing fractures and stimulating bone healing.
“Ken is a proven leader who brings extensive senior management and operational experience to BME, as well as a shared strategic vision to create a leading medical device company,” said
Mr. Moch has served as the President of Euclidean Life Science Advisors, which provides strategic advisory services to life sciences companies, since early 2008. He previously was Managing Director, Healthcare Investment Banking at ThinkEquity Partners and Chairman, President and CEO of Alteon, Inc., a biotech company specializing in small molecule therapeutics for cardiovascular aging and diabetic complications. Mr. Moch earlier served as President and CEO of Biocyte Corporation, the cellular therapy company that pioneered the collection and commercial application of cord blood stem cells, and as a management consultant with McKinsey & Company, Inc. Mr. Moch holds a degree in biochemistry from
“It is a privilege to be joining BME at this exciting time in the company’s history,” said Mr. Moch. “I believe that BME’s unique technology and innovative products have tremendous commercial growth potential. Together with BME’s talented employees, I look forward to accelerating the growth of the Company and broadening the use of our novel memory metal implants.”
“Ken’s involvement is a statement to our distributor partners that we intend to grow our business for our mutual benefit. With in-house manufacturing now on line at BME we have the capability, support and focus for new product development and the continued improvement of our product lines,” said
About BioMedical Enterprises, Inc.
BME designs, manufactures and markets memory metal implants used in orthopaedic reconstructive surgery and fracture management. BME’s patented implant system utilizes the unique properties of the shape memory alloy nitinol to provide controlled long-term compression that enhances the body’s natural healing process in an effort to achieve faster healing times and fewer complications. BME’s barbed and smooth OSStaple(TM) lines of bone fusion implants, part of the OSSforce(TM) fixation system, are designed to achieve controlled long-term compression of bone fragments. BME’s OSSAnchor(TM) line of soft tissue fixation implants give surgeons a simple yet powerful tool to attach soft tissue to bone.
For more information about BME and its unique products visit http://www.bme-tx.com.
SOURCE BioMedical Enterprises, Inc.